Puma Biotechnology director may sell 62K shares

Director Alessandra Cesano filed a Rule 144 notice to potentially sell up to 62,150 PBYI common shares, mainly from option exercise and vested restricted stock.

Rhea-AI Filing Summary

PUMA BIOTECHNOLOGY, INC. (PBYI) is the issuer for a planned resale of its common stock under Rule 144 by director Alessandra Cesano. The notice covers up to 62,150 shares, including 12,150 shares from restricted stock that vested on June 11, 2025 and 50,000 shares issuable from a stock option exercise dated September 14, 2026. The shares are held at Fidelity Brokerage Services LLC and are listed on NASDAQ.

Key Figures

Shares covered by Rule 144 notice: 62,150 shares Restricted stock shares: 12,150 shares Stock option exercise shares: 50,000 shares +2 more

5 metrics

Shares covered by Rule 144 notice 62,150 shares Total PUMA BIOTECHNOLOGY, INC. common stock referenced in this Form 144

Restricted stock shares 12,150 shares Common stock from restricted stock vesting on June 11, 2025

Stock option exercise shares 50,000 shares Common stock tied to a stock option exercise dated September 14, 2026

Brokerage holding shares 62,150 shares PUMA BIOTECHNOLOGY, INC. common stock held at Fidelity Brokerage Services LLC

SEC File Number 001-35703 File number for PUMA BIOTECHNOLOGY, INC.

Key Terms

Rule 144, Restricted Stock Vesting, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 06/11/2025 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Stock Option Exercise financial

"Common | 09/14/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for PBYI?

It discloses that director Alessandra Cesano has filed a Rule 144 notice to potentially sell up to 62,150 shares of PUMA BIOTECHNOLOGY, INC. common stock through Fidelity Brokerage Services LLC, with the shares listed on NASDAQ.

How many PBYI shares are covered by this Rule 144 notice?

The notice covers up to 62,150 shares of PUMA BIOTECHNOLOGY, INC. common stock. This consists of 12,150 shares from vested restricted stock and 50,000 shares associated with a stock option exercise.

What are the sources of the PBYI shares to be sold under this Form 144?

Shares come from two sources: 12,150 restricted shares that vested on June 11, 2025 as compensation, and 50,000 shares tied to a stock option exercise dated September 14, 2026, both relating to PUMA BIOTECHNOLOGY, INC. common stock.

Who is the person selling PBYI shares under this Rule 144 filing?

The person is Alessandra Cesano, identified as a director of PUMA BIOTECHNOLOGY, INC. The Form 144 is signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for her.

When did the PBYI restricted stock and options involved in this Form 144 vest or exercise?

The restricted stock underlying 12,150 shares vested on June 11, 2025. The stock option exercise associated with 50,000 shares is dated September 14, 2026, according to the Form 144 disclosure.

Which broker is handling the planned PBYI share sale under Rule 144?

The broker listed is Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island. The PUMA BIOTECHNOLOGY, INC. common shares covered by the Rule 144 notice are held through this brokerage firm.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 12:06 PM EDT Accepted by SEC EDGAR 09/14/2026 - 12:05 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001827015
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PUMA BIOTECHNOLOGY, INC.
SEC File Number	001-35703
Address of Issuer	10880 WILSHIRE BLVD. SUITE 1700 LOS ANGELES CALIFORNIA 90024
Phone	(424) 248-6500
Name of Person for Whose Account the Securities are To Be Sold	Cesano Alessandra
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	62150	565565.00	51620066	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/11/2025	Restricted Stock Vesting	Issuer			12150	06/11/2025	Compensation
Common	09/14/2026	Stock Option Exercise	Issuer			50000	09/14/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Alessandra Cesano
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)